Meclizine Hydrochloride

Manufacturer
PD-Rx Pharmaceuticals, Inc.
Effective date
2019-10-23
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
9
Source
legacy-cache
Hydrated at
2026-08-02 00:06:13

Label at a glance#

ProductMeclizine Hydrochloride
Active ingredientMECLIZINE HYDROCHLORIDE
Label structure10 sections

Indications and uses

Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system.

Dosage and administration

For the treatment of vertigo associated with diseases affecting the vestibular system, the recommended dose is 25 to 100 mg daily, in divided dosage, depending upon clinical response.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Chemically, meclizine hydrochloride, USP is 1-( p-Chloro-α-phenylbenzyl)-4-( m-methylbenzyl) piperazine dihydrochloride monohydrate. The molecular weight is 481.88 g/mole.

Meclizine Structural Formula
Meclizine Structural Formula

Meclizine hydrochloride tablets, USP are available in two different strengths, 12.5 mg and 25 mg.

Inert ingredients for the tablets are: anhydrous lactose, colloidal silicon dioxide, crospovidone, magnesium stearate and microcrystalline cellulose.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Meclizine hydrochloride is an antihistamine that shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

Pharmacokinetics

PHARMACOKINETICS SECTION

The available pharmacokinetic information for meclizine following oral administration has been summarized from published literature.

Absorption

SPL UNCLASSIFIED SECTION

Meclizine is absorbed after oral administration with maximum plasma concentrations reaching at a median T max value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form.

Distribution

SPL UNCLASSIFIED SECTION

Drug distribution characteristics for meclizine in humans are unknown.

Metabolism

SPL UNCLASSIFIED SECTION

The metabolic fate of meclizine in humans is unknown. In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine.

The genetic polymorphism of CYP2D6 that results in extensive-, poor-, intermediate- and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.

Elimination

SPL UNCLASSIFIED SECTION

Meclizine has a plasma elimination half-life of about 5-6 hours in humans.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Meclizine hydrochloride tablets are contraindicated in individuals who have shown a previous hypersensitivity to it.

WARNINGS

WARNINGS SECTION

Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.

Patients should avoid alcoholic beverages while taking this drug.

Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.

PRECAUTIONS

PRECAUTIONS SECTION

Pediatric Use

PEDIATRIC USE SECTION

Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.

Pregnancy Use

PREGNANCY SECTION

Pregnancy Category B

SPL UNCLASSIFIED SECTION

Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when meclizine is administered to a nursing woman.

Hepatic Impairment

SPL UNCLASSIFIED SECTION

The effect of hepatic impairment on the pharmacokinetics of meclizine has not been evaluated. As meclizine undergoes metabolism, hepatic impairment may result in increased systemic exposure of the drug. Treatment with meclizine should be administered with caution in patients with hepatic impairment.

Renal Impairment

SPL UNCLASSIFIED SECTION

The effect of renal impairment on the pharmacokinetics of meclizine has not been evaluated. Due to a potential for drug/metabolite accumulation, meclizine should be administered with caution in patients with renal impairment and in the elderly as renal function generally declines with age.

Drug Interactions

DRUG INTERACTIONS SECTION

There may be increased CNS depression when meclizine is administered concurrently with other CNS depressants, including alcohol, tranquilizers, and sedatives (see  WARNINGS).

Based on in vitro evaluation, meclizine is metabolized by CYP2D6. Therefore there is a possibility for a drug interaction between meclizine and CYP2D6 inhibitors.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Anaphylactoid reaction, drowsiness, dry mouth, headache, fatigue, vomiting and, on rare occasions, blurred vision have been reported.

To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

For the treatment of vertigo associated with diseases affecting the vestibular system, the recommended dose is 25 to 100 mg daily, in divided dosage, depending upon clinical response.

HOW SUPPLIED

HOW SUPPLIED SECTION

Meclizine Hydrochloride Tablets, USP are available containing 25 mg of meclizine hydrochloride, USP.

The 25 mg tablets are white to off-white, round, unscored tablets debossed with M on one side of the tablet and MCZ over 25 on the other side. They are available as follows:

NDC 43063-662-10
bottles of 10 tablets

NDC 43063-662-15
bottles of 15 tablets

NDC 43063-662-30
bottles of 30 tablets

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PRINCIPAL DISPLAY PANEL - 25 mg

Meclizine

Hydrochloride

Tablets, USP

25 mg

PACKAGE LABEL.PRINCIPAL DISPLAY PANELPACKAGE LABEL.PRINCIPAL DISPLAY PANEL

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
43063-662-10EA - Each43063-662c598e380-cc15-4cd6-a914-8a177cf56d0c12016-10-06
43063-662-15EA - Each43063-662b61d399f-5fa4-4832-8b6b-07e73e98648b12017-04-05
43063-662-30EA - Each43063-66247c9fe21-994b-400d-8e47-738d25322bf612016-04-04
0378-5486-10EA - Each0378-5486d8175ebd-ee68-4f54-a916-f32260a4615e12013-02-13
0378-5486-77EA - Each0378-548621806760-f7d0-4722-951b-18afaadb628512013-02-13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
43063-66243063-662-10, 43063-662-15, 43063-662-30
0378-5486

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A202640-001MECLIZINE HYDROCHLORIDEMECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17
A202640-002MECLIZINE HYDROCHLORIDEMECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17
A202640-003MECLIZINE HYDROCHLORIDEMECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 3 matching rows.

Application-product, TE code table
Application-productTE code
A202640-001AA
A202640-002AA
A202640-003AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 129 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-1784e616aacf4f…
2026-09-14 22:38:342026-08A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-1784e616aacf4f…
2026-09-14 22:38:342026-08A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-1784e616aacf4f…
2026-08-18 06:07:402026-07A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17caaa826d4ba7…
2026-08-18 06:07:402026-07A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17caaa826d4ba7…
2026-08-18 06:07:402026-07A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17011fe1cb6892…
2026-02-19 14:30 UTC2026-02A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17011fe1cb6892…
2026-02-19 14:30 UTC2026-02A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-1731067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-1731067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-1731067a03dcf5…
2025-08-23 18:47 UTC2025-08A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-176a471c1ec25d…
2025-08-23 18:47 UTC2025-08A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-176a471c1ec25d…
2025-08-23 18:47 UTC2025-08A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-176a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-1703ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-1703ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-1703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-172680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-172680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-172680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-175bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-175bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-175bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17d06236e962d9…
2024-10-29 15:01 UTC2024-10A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17d06236e962d9…
2024-10-29 15:01 UTC2024-10A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-1779d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-1779d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-1779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17301d65b070ca…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 74 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A202640-001AA184e616aacf4f…
2026-09-14 22:38:342026-08A202640-002AA184e616aacf4f…
2026-09-14 22:38:342026-08A202640-003AA184e616aacf4f…
2026-08-18 06:07:402026-07A202640-001AA1caaa826d4ba7…
2026-08-18 06:07:402026-07A202640-002AA1caaa826d4ba7…
2026-08-18 06:07:402026-07A202640-003AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A202640-001AA1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A202640-002AA1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A202640-003AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-001AA131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-002AA131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-003AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A202640-001AA16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A202640-002AA16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A202640-003AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-001AA1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-002AA1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-003AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-001AA1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-002AA1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-003AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-001AA103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-002AA103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-003AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-001AA12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-002AA12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-003AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-001AA15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-002AA15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-003AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-001AA1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-002AA1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-003AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A202640-001AA1d06236e962d9…
2024-10-29 15:01 UTC2024-10A202640-002AA1d06236e962d9…
2024-10-29 15:01 UTC2024-10A202640-003AA1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A202640-001AA179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A202640-002AA179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A202640-003AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A202640-001AA1301d65b070ca…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
9595a664-b780-d726-e053-2995a90a20432d125ea4-5431-5b4e-e054-00144ff88e882019-10-23Warnings, Adverse reactionsExact identifier
spl id: 9595a664-b780-d726-e053-2995a90a2043
spl set id: 2d125ea4-5431-5b4e-e054-00144ff88e88

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.